Diabetic retinopathy screenings offered this week through Ainnova partnerships

Free diabetic retinopathy (DR) screenings begin this week through a collaboration between Avant Technologies, Ainnova Tech and Grupo Dökka, Fischel Pharmacies and La Bomba Pharmacies, according to a press release.1 Ainnova utilizes artificial intelligence (AI) in their efforts of early disease detection.

Diabetic customers of Fischel and La Bomba Pharmacies have been asked to schedule a free DR screening through a partnership program utilizing Ainnova’s AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive retina scan.

DR is a leading cause of vision loss in patients with diabetes. Screening for DR is essential for prevention, to detect changes in the retina before vision is affected.

“As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment – connecting every step of the journey,” Vinicio Vargas, chief executive officer at Ainnova said in a press release. “We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient.”

Vargas continued, “Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way – where the biggest winners are the patients.”

References:

1. Avant Technologies Inc. Avant Technologies’ JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies. Prnewswire.com. Published June 17, 2025. Accessed June 18, 2025. https://www.prnewswire.com/news-releases/avant-technologies-jv-partner-ainnova-begins-diabetic-retinopathy-screenings-with-leading-pharmacies-302483739.html